1. Home
  2. GRFS vs HAE Comparison

GRFS vs HAE Comparison

Compare GRFS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$7.31

Market Cap

4.9B

Sector

Health Care

ML Signal

N/A

HAE

Haemonetics Corporation

N/A

Current Price

$104.53

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRFS
HAE
Founded
1940
1971
Country
Spain
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.8B
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
GRFS
HAE
Price
$7.31
$104.53
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$10.87
★ $111.50
AVG Volume (30 Days)
375.7K
★ 455.3K
Earning Date
07-28-2022
11-05-2026
Dividend Yield
★ 1.17%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.72
Revenue
N/A
★ $910,373,000.00
Revenue This Year
$1.73
$6.21
Revenue Next Year
$6.26
$5.54
P/E Ratio
★ $18.67
$146.44
Revenue Growth
★ N/A
N/A
52 Week Low
$6.96
$48.17
52 Week High
$10.16
$110.45

Technical Indicators

Market Signals
Indicator
GRFS
HAE
Relative Strength Index (RSI) 41.48 56.66
Support Level $7.21 $100.53
Resistance Level $8.41 $110.01
Average True Range (ATR) 0.10 2.49
MACD -0.00 -0.77
Stochastic Oscillator 36.67 31.19

Price Performance

Historical Comparison
GRFS
HAE

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Share on Social Networks: